AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7573470
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of H2SO4 aerosol (1,000 microgram/m3)
Trial: 7573470
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of NaCl aerosol (control)
Trial: 19636555
Drug: Oral leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 4 hours before surgery
Trial: 19636555
Drug: Oral leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 12 hours before surgery
Trial: 19636555
Drug: Oral leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leucovorin (LV) at a single dose of 25 mg administered 18 hours before surgery
Trial: 19636555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LV administration)
Trial: 15265397
Drug: Submucosal injection
RxNorm normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection of pirarubicin
Trial: 3158675
Drug: Zimelidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 200 mg/24 hours for 10 days
Trial: 3158675
Drug: Ethanol 0.5
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.5 and 1.0 g/kg of body weight
Trial: 29747432
Drug: Mangosteen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangosteen extract with behavioral therapy
Trial: 12814445
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose insulin (6 pmol min-1) + C-peptide (2-60 pmol min-1)
Trial: 12814445
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose insulin (30 pmol min-1) + C-peptide
Trial: 12814445
Drug: C-peptide (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide (during low dose insulin)
Trial: 2568765
Drug: Lofexidine (L)
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine (L)
Trial: 20889523
Drug: High-dose vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamins C and E (1000 mg vitamin C and 400 IU RRR α-tocopherol daily)
Trial: 11918761
Drug: Bicarbonate-buffered PD
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-buffered PD solution (34 mmol/L, pH 7.4)
Trial: 11918761
Drug: Lactate-buffered PD
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-buffered PD solution (35 mmol/L, pH 5.5)
Trial: 11918761
Drug: Both bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both bicarbonate and lactate buffered PD solutions
Trial: 7762389
Drug: Oxymetazoline nasal
RxNorm normalized name: oxymetazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline nasal spray once daily at night
Trial: 7762389
Drug: Oxymetazoline nasal
RxNorm normalized name: oxymetazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline nasal spray three times daily
Trial: 2221729
Drug: Trimetazidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (3 tablets daily for one month)
Trial: 342043
Drug: Topical ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ampicillin (1 g applied to the wound)
Trial: 6196515
Drug: High-dose neuraminidase-treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose neuraminidase-treated allogeneic blasts
Trial: 6196515
Drug: Specific monoclonal
RxNorm normalized name: Bispecific monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific monoclonal antibodies or autologous cytotoxic T-cells
Trial: 26802011
Drug: Patient-centered, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered, tablet computer-based self-monitoring system
Trial: 25503160
Drug: Polaprezinc in
RxNorm normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc in sodium alginate suspension (P‐AG)
Trial: 20854207
Drug: Dapivirine gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9
Trial: 20854207
Drug: Dapivirine gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine gel (0.001%, 0.005%, or 0.02%)
Trial: 11950252
Drug: Valdecoxib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 5 mg
Trial: 12209034
Drug: Valdecoxib 10
RxNorm normalized name: valdecoxib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 10 mg
Trial: 12100776
Drug: Valdecoxib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 5 mg and 10 mg
Trial: 2803090
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg/d)
Trial: 26014292
Drug: Dexrazoxane (10:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexrazoxane (10:1 ratio with doxorubicin, cumulative dose of 100 to 360 mg/m2)
Trial: 23862400
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium hyaluronate 9 mg twice daily for 30 days
Trial: 18579227
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol)
Trial: 10716083
Drug: Moxifloxacin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (1 x 400 mg tablet in the morning and 1 placebo tablet in the evening for 7 days)
Trial: 10716083
Drug: Clarithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (1 x 500 mg tablet in the morning and 1 x 500 mg tablet in the evening for 7 days)
Trial: 31301609
Drug: Daily patient-reported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily patient-reported anxiety measured using smartphones
Trial: 28840585
Drug: Quxie Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quxie Capsule combined with conventional therapy
Trial: 28840585
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with conventional therapy
Trial: 8844447
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 1005 (250 mg twice daily)
Trial: 8844447
Drug: theophylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: theophylline (400 mg twice daily)
Trial: 8844447
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 1005 and theophylline concomitantly (treatment C)
Trial: 1621751
Drug: Loracarbef (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef (200 mg, twice daily)
Trial: 1621751
Drug: Cefaclor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (250 mg, three times daily)
Trial: 6463091
Drug: d-amphetamine (5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (5-30 mg)
Trial: 28741741
Drug: Pregabalin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin after low dose of morphine
Trial: 26803590
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 and folic acid/B12 treatment
Trial: 26803590
Drug: Folic acid/B12
RxNorm normalized name: iron/folic acid/B12/C/docusate 90 mg-1 mg-12 mcg-120 mg-50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid/B12 treatment
Trial: 18753861
Drug: Entecavir 1
RxNorm normalized name: entecavir 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg once daily for 24 weeks
Trial: 12540412
Drug: Acipimox (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (500 mg at -90 and 0 min)
Trial: 8510517
Drug: Recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant growth hormone (rGH) therapy for 12 months
Trial: 27223641
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg orally, twice daily preoperatively, and 0.5 mg, twice daily until hospital discharge)
Trial: 24329187
Drug: Risperidone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 2.5 mg
Trial: 10461448
Drug: Ceftibuten 400
RxNorm normalized name: ceftibuten 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 400 mg or 9 mg/kgbw/day (Group B)
Trial: 10461448
Drug: Parenteral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral therapy (Group A)
Trial: 8150836
Drug: Collagenase ointment
RxNorm normalized name: collagenase Topical Ointment
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase ointment and polymyxin B sulfate/bacitracin spray
Trial: 4343464
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with diazepam alone
Trial: 4343464
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with diazepam and atropine
Trial: 4343464
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with chlormethiazole
Trial: 28627290
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal block (ACB) with 0.2% ropivacaine, 20 mL bolus followed by continuous flow at 6 mL/h for 2 days
Trial: 28627290
Drug: Single-dose local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose local infiltration anesthesia (LIA) alone
Trial: 24350813
Drug: Risperidone (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (maximum weight-based dose of 1.25 mg/day for 20 to <45 kg, and 1.75 mg/day for ≥ 45 kg)
Trial: 26676082
Drug: Augmentation procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation procedure
Trial: 24911814
Drug: Pain Group
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Group (topical capsaicin cream)
Trial: 23213981
Drug: Medication (salvia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (salvia injectio and mecobalamin)
Trial: 16415626
Drug: Infant massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant massage (tactile and kinesthetic stimulation), administered twice daily for 10 days.
Trial: 12444335
Drug: 0.12% betamethasone‐17‐valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% betamethasone‐17‐valerate ointment
Trial: 17429636
Drug: LEF (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEF (100 mg/day for 3 days followed by 20 mg/day)
Trial: 17429636
Drug: MTX (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (25 mg once weekly)
Trial: 8489567
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation (300 mg, applied twice a day)
Trial: 8489567
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation (400 mg, applied once a day in the evening)
Trial: 8489567
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation (300 mg)
Trial: 8489567
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation (400 mg)
Trial: 3583456
Drug: Oral nourishment
RxNorm normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nourishment
Trial: 3583456
Drug: Intravenous nourishment
RxNorm normalized name: Lantiseptic Nourishing Skin
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nourishment
Trial: 3583456
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous nourishment
Trial: 29957714
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (twice daily sessions of manual mobilization and 30‐minute passive/active cycling therapy)
Trial: 27248838
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (aPDT)
Trial: 27248838
Drug: Tongue scraper
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue scraper and photodynamic therapy
Trial: 23002547
Drug: Kurarinol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kurarinol (single drug group)
Trial: 19501011
Drug: Comprehension questionnaire
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehension questionnaire administered at the end of the clinical trial
Trial: 18396361
Drug: Na-ASP-2 vaccine
RxNorm normalized name: sodium lauroyl aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-ASP-2 vaccine (10 microg)
Trial: 18396361
Drug: Na-ASP-2 vaccine
RxNorm normalized name: sodium lauroyl aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-ASP-2 vaccine (50 microg)
Trial: 18396361
Drug: Na-ASP-2 vaccine
RxNorm normalized name: sodium lauroyl aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-ASP-2 vaccine (100 microg)
Trial: 15647416
Drug: Anidulafungin 200
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anidulafungin 200 mg intravenous loading dose followed by 100 mg intravenous maintenance dose (days 2-8)
Trial: 15647416
Drug: Cyclosporine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 1.25 mg/kg oral solution twice daily (days 5-8)
Trial: 10470636
Drug: Spinal Anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Anesthesia (10 mg of hyperbaric tetracaine intrathecally)
Trial: 10470636
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia (fentanyl i.v. 1 to 2 micrograms/kg, propofol i.v. 1.0 to 2.0 mg/kg, isoflurane end-tidal 0.7% to 1.2%, 70% nitrous oxide in oxygen)
Trial: 28364511
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Active Behavioral Desensitization Control (BD)
Trial: 17251875
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (50 mg/kg bolus followed by 8.3 mg/kg/hr infusion for 24 hr)
Trial: 15835374
Drug: Micardis (Telmisartan)
RxNorm normalized name: telmisartan Oral Tablet [Micardis]
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micardis (Telmisartan) with low-dose aspirin
Trial: 12207634
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg methotrexate (MTX)
Trial: 12207634
Drug: AUC(24,36 h)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC(24,36 h) >= 700 nmol l(‐1) h
Trial: 12207634
Drug: AUC(24,36 h)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC(24,36 h) < 700 nmol l(‐1) h
Trial: 8951627
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg 1 x daily for 3 days
Trial: 1758817
Drug: MS Contin
RxNorm normalized name: MS Contin
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS Contin tablet 200 mg (controlled release morphine sulphate)
Trial: 27199859
Drug: Animal Assisted
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal Assisted Therapy (AAT) treatment group (n = 14) participated in twice-weekly 1-hour sessions of AAT
Trial: 21353111
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone (10 mg/kg)
Trial: 21353111
Drug: Ibuprofen combined
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen combined with acetaminophen (10 mg/kg ibuprofen + 15 mg/kg acetaminophen)
Trial: 21353111
Drug: Ibuprofen followed
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen followed by acetaminophen (10 mg/kg ibuprofen followed by 15 mg/kg acetaminophen 3 hours later)
Trial: 16754526
Drug: Limited intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited intervention (one visit with asthma self‐management education and provision of inhaled budesonide)
Trial: 9289706
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients with disturbances in carbohydrate and lipid metabolism
Trial: 9289706
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients with disturbance in lipid metabolism
Trial: 1475671
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene motivation tool (Parograph)
Trial: 6228196
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (13‐cis‐retinoic acid) for four months
Trial: 27302514
Drug: Photon radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photon radiation therapy (XRT)
Trial: 19653744
Drug: Presentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation of letters pairs (e.g., A-Z)
Trial: 19653744
Drug: Presentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation of mixed digit-letter pairs (e.g., 1-Z)
Trial: 17326881
Drug: Dinoprostone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (0.5 mg PGE(2) gel intracervically every 6 h, max three doses in 24 h)
Trial: 15871365
Drug: Itopride hydrochloride
RxNorm normalized name: Itopride hydrochloride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride hydrochloride (Ganaton) 50 mg three times daily for 2 weeks
Trial: 15871365
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate 5 mg three times daily for 2 weeks
Trial: 9531075
Drug: Thymostimulin, 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin, 70 mg i.m. qd for the first month and every other day thereafter
Trial: 9531075
Drug: Short-term antimicrobial
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term antimicrobial chemoprophylaxis with pefloxacin (800 mg i.v. qd for the first 4 days) and polychemotherapy with teicoplanin (800 mg i.v. qd) and netilmicin (300 mg i.m. qd)
Trial: 25511214
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg fentanyl added to 0.5% bupivacaine
Trial: 25511214
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline mixed with 10 ml of 0.5% bupivacaine
Trial: 18072125
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of droperidol (DROP) IM
Trial: 14715050
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (specific drugs not mentioned)
Trial: 14715050
Drug: High-potency antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency antipsychotics coadministered with inhibitors such as clarithromycin
Trial: 3288683
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 mg, three doses over 14 hours)
Trial: 3288683
Drug: Ketotifen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (200 ng intradermal PAF)
Trial: 31036048
Drug: Endoscopic sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sinus surgery (ESS) plus intranasal medication
Trial: 31036048
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg) plus intranasal medication
Trial: 31036048
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus intranasal medication
Trial: 21988668
Drug: 3-week titration
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week titration (weekly quarter-dose increments over 3 weeks to full dose [30 µg])